In This Section

New Strategies for Augmenting Immune Checkpoint Blockade in Cancer Therapy

Saturday April 06, 2019

11:00 am - 1:00 pm Eastern Time (ET)

Room W205 A


Chair :

John Lazo
University of Virginia

Christine Canman
University of Michigan

Immune Checkpoint Blockade is a powerful new weapon against cancer. Unfortunately, only a fraction of patients achieve remission. Current research is directed towards finding biomarkers that would help identify likely responders and develop new therapeutic approaches to transform non-responders to responders. This symposium will provide a historical perspective on the field of immune-oncology and discuss recent progress in identifying new strategies for boosting the efficacy of immune checkpoint inhibitors through combination therapy with ATM and DNA methylation transferase inhibitors.


Benjamin Youngblood - St. Jude Children’s Research Hospital

Reversing Exhaustion-associated DNA-methylation Programs to Re-invigorate Exhausted Cytotoxic T Cells and Improve Immune Checkpoint Inhibitors Response

Katherine Chiappinelli - The George Washington University School of Medicine and Health Sciences

Epigenetic Activation of the Interferon Response to Sensitize Cancers to Immune Therapy

Michael Green - University of Michigan

Inhibition of the ATM Kinase – A New Approach to Enhancing Immune Therapy for the Treatment of Pancreatic Cancer

Last Updated: August 15, 2019
Key Dates
April 6

ASPET Business Meeting and Awards Presentation

April 6-9

ASPET Annual Meeting at EB 2019